中国肺癌杂志2013，Vol.16Issue(3)：138-143,6.DOI:10.3779/j.issn.1009-3419.2013.03.04
埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析
Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
宋正波 1余新民 1蔡菊芬 1邵岚 1林宝钗 1何春晓 1张贝贝 1张沂平1
作者信息
摘要
Abstract
Background and objective As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phaseⅢ clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung cancer (NSCLC) compared with gefitinib. This retrospective study aims to evaluate the efficacy and tolerability of icotinib monotherapy for advanced NSCLC patients with EGFR mutation and wild-type patients in our hospital. Methods Patients with advanced NSCLC who were treated with icotinib in Zhejiang Cancer Hospital were retrospectively analyzed from August, 2011 to August, 2012. Survival was estimated using Kaplan-Meier analysis and Log-rank tests. Results The clinical data of 49 patients (13 with wild-type and 36 with EGFR mutation) with NSCLC were enrolled in the current study. The patients' overall objective response rate (ORR) was 58.3% and the disease control rate (DCR) in 36 EGFR mutation patients was 88.9%. The ORR was 7.7% and DCR was 53.8% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 9.5 months and 2.2 months in wild-type patients (P<0.001). Nineteen patients with EGFR mutation received icotinib as first-line and 17 in further-line treatment. The PFS was 9.5 months in the first-line and 8.5 months for second-line or further-line patients (P=0.41). Median overall survival (OS) in EGFR mutation patients was not reached, but was 12.6 months in wild-type patients. Most of the drug-related adverse events were mild (gradeⅠ or Ⅱ) and reversible with no grade Ⅳ toxicity. Conclusion Icotinib monotherapy showed significant antitumor activity in advanced NSCLC EGFR mutation patients. The toxicity was well tolerated and acceptable.关键词
肺肿瘤/埃克替尼/EGFR突变/疗效Key words
Lung neoplasms/Icotinib/EGFR mutation/Efficacy分类
医药卫生引用本文复制引用
宋正波,余新民,蔡菊芬,邵岚,林宝钗,何春晓,张贝贝,张沂平..埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析[J].中国肺癌杂志,2013,16(3):138-143,6.
